A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

NCT04834973 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient Patient Recruitment Rates

Conditions

Melanoma

Interventions

DRUG: tigilanol tiglate
DRUG: pembrolizumab

Sponsor

QBiotics Group Limited

Collaborators

[object Object]